Loading clinical trials...

Your health journey, clearly organized.

Legal

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | Clinical Trials | Clareo Health

Back to search

WITHDRAWNPhase 2

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

A Phase II Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Advanced Non-Small Cell Lung Cancer

NCT02950038•M.D. Anderson Cancer Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Lung Cancer, Nonsmall Cell, Stage I

Interventions

Ibrutinib

Nivolumab

Key Dates

Start Date

December 1, 2016

Primary Completion Date

December 1, 2019

Last Updated

February 13, 2017

Sponsors

Lead Sponsor

M.D. Anderson Cancer Center

Collaborators

Janssen Scientific Affairs, LLC

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 13, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions